|Synonyms||SKL-N05, ADX-N05, ARL-N05, and JZP-110; (R)-2-amino-3-phenylpropylcarbamate hydrochloride|
|Chemical and physical data|
|Molar mass||194.234 g/mol g·mol−1|
|3D model (JSmol)|
Aerial ran two Phase II trials of the drug in narcolepsy before selling the license to solriamfetol to Jazz in 2014; Jazz paid Aerial $125 million up front and will pay Aerial and SK up to $272 million in milestone payments, and will pay double digit royalties to SK.
Solriamfetol had also been tested in animal models of depression, but as of 2017 that work had not been advanced to clinical trials. During development it has been called SKL-N05, ADX-N05, ARL-N05, and JZP-110.
In March 2018 the FDA accepted SK's and Jazz' NDA for use of solriamfetol to treat excessive sleepiness in people with narcolepsy or obstructuve sleep apnea; the drug has an orphan designation for narcolepsy.
- Abad, VC; Guilleminault, C (2017). "New developments in the management of narcolepsy". Nature and Science of Sleep. 9: 39–57. doi:10.2147/NSS.S103467. PMC 5344488. PMID 28424564.
- Ji-young, Sohn (5 March 2018). "SK Biopharmaceuticals' narcolepsy drug on track to hitting US market". The Korea Herald.
- Sullivan, SS; Guilleminault, C (2015). "Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy". Expert Opinion on Emerging Drugs. 20 (4): 571–82. doi:10.1517/14728214.2015.1115480. PMID 26558298.
- Garde, Damian (January 14, 2014). "Jazz bets up to $397M on Aerial's narcolepsy drug". FierceBiotech.
- de Biase, S; Nilo, A; Gigli, GL; Valente, M (August 2017). "Investigational therapies for the treatment of narcolepsy". Expert Opinion on Investigational Drugs. 26 (8): 953–963. doi:10.1080/13543784.2017.1356819. PMID 28726523.
- "Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals". AdisInsight. Retrieved 15 April 2018.